Bud Genius Announces Important Addition to Advisory Board

Dr. Peter Wilson taught Accounting at Duke University and served as Director of the Executive MBA Program

Bud Genius, Inc. (OTC: RIGH), a leading laboratory for cannabis testing and profiling, developer of data-driven rating systems for marijuana strains, brand and retail development specialist, and licensee of celebrity-endorsed marijuana and hemp related merchandise, announced today an addition to their Executive Advisory Board.

Peter Wilson, Ph.D., a well known and highly respected expert in accounting, financial reporting and business law, is joining the Bud Genius Executive Advisory Board in an official capacity to lend his expertise and insight as the company enters its rapid growth phase.

Dr. Wilson has over 25 years of experience in corporate finance and spent 19 years at Duke University’s Fuqua School of Business where he was a member of the accounting faculty and also served as the Director of Executive MBA Programs.

Prior to his time at Duke, Dr. Wilson taught at the Stern School of Business at New York University in the graduate and undergraduate programs and also served as the Director of the Undergraduate Program in Accounting, Taxation and Business Law.

“We are pleased to have Dr. Wilson join our company’s Executive Advisory Board and look forward to his contributions,” said Angel Stanz, company CEO. “As an expert in corporate finance, accounting and financial reporting, Dr. Wilson will provide expertise in areas that can profoundly impact the future of our company.”

Dr. Wilson holds a BA degree in Philosophy from the University of North Carolina at Chapel Hill, an MBA degree from UNC-Greensboro, and a Ph.D. degree in Accounting from the University of North Carolina at Chapel Hill.

For more information on Bud Genius, call (855) 723-3283, or visit BGMedtech.com

About Bud Genius:

An early leader in the cannabis industry, Bud Genius is one of the first established analytical cannabis laboratories in the United States. Bud Genius launched to bring vendors together with doctors, patients, and dispensaries that require certified products held to demanding standards. Bud Genius’ mission is to expand across the US and abroad, serving as the beacon of quality for medical cannabis and adult-use marijuana through the formation of regional laboratories, strain certification, data collection, online reporting, and product development.

For more information please visit: www.BGMedtech.comVisit the Bud Genius Cannabis Showroom at: www.BudGenius.com

Connect:

Website: www.BGMedtech.comTwitter: Twitter.com/BudGeniusCannabis Showroom: www.BudGenius.com

Forward Looking Statements:

This press announcement includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of company’s management and are subject to significant risks and uncertainties. Forward-looking statements that can be identified by such terminology such as "believes," "expects," "potential," "plans," "suggests," "may," "should," "could," "intends," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management's expectations could be affected by, among other things, uncertainties relating to our success in completing acquisitions, financing our operations, entering into strategic partnerships, competitive factors, and other matters. Forward-looking statements speak only as to the date they are made. The Company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.

Bud Genius, Inc.Randall HuftPublic Relations855-723-3283Randall@BudGenius.com

RightSmile (CE) (USOTC:RIGH)
Historical Stock Chart
From Mar 2024 to Apr 2024